Medtronic's Hugo robot wins CE mark for vessel-sealing technology
LigaSure is indicated for sealing and cutting vessels, thick tissue, and lymphatics up to 7mm in diameter and expands Hugo's capabilities in areas such as gynaecologic and urologic procedures. According to Medtronic, LigaSure seals vessels within two seconds and minimises thermal spread to surrounding tissue.
Medtronic senior vice-president Matt Anderson said: 'With CE mark for LigaSure RAS, Medtronic is fulfilling a promise to customers to integrate our trusted vessel-sealing technology onto the Hugo RAS system.
'More than fulfilling a commitment, this regulatory approval is a big step forward as we continue to shape the future of surgery.'
Hugo has been in use in Europe since 2022 and was recently recommended by the National Institute for Health and Care Excellence (NICE) as one of 11 surgical robots set to be used across the UK National Health Service (NHS).
While Hugo is not yet available in the US, Medtronic's submission for a urology indication for the robot is currently under review with the US Food and Drug Administration (FDA), with US market entry expected later this year.
In anticipation of Hugo's approval with the FDA, Medtronic is currently building out its training provision for the RAS system following the introduction of live streaming to its Touch Surgery Ecosystem (TSE) last year. The broad aim of Medtronic's surgical training provision is to enhance and democratise surgical education on a global scale, removing barriers to training such as geographic location.
With its da Vinci surgical robot, Intuitive Surgical currently holds the largest share of the global robotic surgery market at almost 60%, according to GlobalData analysis. The market is forecast to reach a valuation of $9.2bn by 2034, up from around $2.9bn in 2024.
Due to Medtronic's size, the Hugo is expected to pose the main challenge to Intuitive's da Vinci robot once the former is approved in the US.
According to GlobalData analyst Grayson Vigneux, due to Intuitive's 20-year head start in the US robotic surgery market, its vast installed base and long-standing reputation, Hugo is 'more likely to capture new customers rather than immediately displace Intuitive's existing market'.
"Medtronic's Hugo robot wins CE mark for vessel-sealing technology" was originally created and published by Medical Device Network, a GlobalData owned brand.
The information on this site has been included in good faith for general informational purposes only. It is not intended to amount to advice on which you should rely, and we give no representation, warranty or guarantee, whether express or implied as to its accuracy or completeness. You must obtain professional or specialist advice before taking, or refraining from, any action on the basis of the content on our site.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
a day ago
- Yahoo
Are Wall Street Analysts Bullish on Medtronic Stock?
Headquartered in Galway, Ireland, Medtronic plc (MDT) develops, manufactures, and sells device-based medical therapies. With a market cap of approximately $115 billion, the company derives revenue from four core segments: Cardiovascular Portfolio, Medical Surgical Portfolio, Neuroscience Portfolio, and Diabetes. MDT stock has surged 10.6% over the past year, trailing behind the S&P 500 Index ($SPX), which surged by 21.1% during the same period. However, year-to-date, MDT stock has advanced by 11.9%, outpacing the S&P 500's 7.9% gain. More News from Barchart Supermicro's Earnings Selloff Explained: Should You Buy SMCI Stock Now? Amazon's $36M Bet on Quantum Computing: What Investors Need to Know AMD Stock Slips After Q2 Earnings, But Here's Why It's a Buying Opportunity Get exclusive insights with the FREE Barchart Brief newsletter. Subscribe now for quick, incisive midday market analysis you won't find anywhere else. Focusing on the industry, MDT has surpassed the S&P Healthcare Equipment SPDR's (XHE) decline of 8.3% over the past year and a 13.3% drop year-to-date. On July 21, Medtronic announced that it had received CE Mark approval for its MiniMed 780G insulin delivery system. The market initially responded cautiously, but by the next trading session, shares had risen by nearly 2.2%. For the current year, ending in April 2026, analysts anticipate MDT to achieve EPS growth of 1.1%, reaching $5.55 on a diluted basis. Notably, Medtronic has consistently beaten consensus estimates over the past four quarters. Among 30 analysts covering MDT stock, the consensus rating is a "Moderate Buy," comprising 13 "Strong Buy" ratings, one "Moderate Buy," 15 "Holds," and one 'Strong Sell.' The current analyst sentiment is slightly more bullish than two months ago, when MDT had a total of 12 "Strong Buy" ratings. On Jul. 16, Mizuho Financial Group, Inc.'s (MFG) Anthony Petrone raised his price target from $98 to $100, while maintaining an 'Outperform' stance. He believes Medtronic is well-positioned within the medical technology sector. Similarly, on Jul. 15, Morgan Stanley (MS) bumped its price target from $98 to $107, reaffirming its 'Overweight' rating. The firm sees continued relative stability in procedure volumes and capital spending trends across hospitals as a reason to stay constructive on the industry, and on Medtronic in particular. The mean price target of $95.83 represents a 7.2% premium to MDT's current price levels. Meanwhile, the Street-high price target of $110 suggests a potential upside of 23.1%. On the date of publication, Kritika Sarmah did not have (either directly or indirectly) positions in any of the securities mentioned in this article. All information and data in this article is solely for informational purposes. This article was originally published on Sign in to access your portfolio
Yahoo
a day ago
- Yahoo
Inside Dexcom's strategy to stay ahead in the $13.6bn CGM market
Dexcom stands as the US leader in the continuous glucose monitoring (CGM) space as it continues to innovate and diversify its product lines to simplify blood glucose monitoring for type 2 diabetes (T2D) patients. The global diabetes population is projected to hit 643 million by 2030, as per the International Diabetes Federation (IDF). According to GlobalData analysis, the global CGM market is growing at a CAGR of 8.62% and is projected to reach a valuation of $13.6bn by 2034, up from $5.9bn in 2024. In the US, Dexcom held an estimated 74% share of the CGM market in 2024. Other major players in the CGM space include Abbott with its FreeStyle Libre CGM system and Medtronic with its MiniMed CGM. A strong constituent of Dexcom's continued US market lead is in the diversification of its CGM technology, with smartphone integrations for its G7 CGM system, the recent roll out of over-the-counter (OTC) CGM Stelo, claimed to be the first glucose biosensor available in the US without a prescription, and recent collaborations that aim to tap into the booming wellness wearables market. According to a 2023 report from GlobalData, the wearable technology market is forecast to grow from $99.5bn in 2022 to $290.6bn in 2030. In 2024, Dexcom invested $75m into ŌURA, forging a partnership that makes Dexcom the only CGM compatible with the Finnish company's Oura smart ring. The Oura smart ring, which measures wellness metrics such as sleep, stress, and cardiovascular data, and CGM data, has so far sold around 2.5 million units worldwide, following Dexcom's investment. In addition, Dexcom leads in native integration with Apple Watch, standing as the only company currently offering direct-to-watch connectivity with its G7 sensor since integrating with the wearable in June 2024. Dexcom recently announced Q2 2025 revenues exceeding $1.1bn, a 15% uplift on Q2 2024. The company also revealed that from 1 January 2026, Dexcom's chief operating officer, Jake Leach, will take over from outgoing CEO Kevin Sayer as Dexcom's new CEO. In Dexcom's 30 July earnings call, Sayer said: 'Today's announcement of Jake's transition to the role of CEO reflects the Board's comprehensive succession planning and their confidence in Jake's leadership throughout his tenure. We are confident that he is the right leader to build on Dexcom's momentum and extend the company's growth well into the future.' Medical Device Network sat down with Sayer to learn more about how the company will maintain its market position and drive innovation in the CGM space in the future. This interview has been edited for length and clarity. Ross Law (RL): How do you expect Dexcom's role to evolve over the next 3-5 years as the CGM space continues to grow more competitive? Kevin Sayer (KS): I think we'll continue to be a leader. We have grown dramatically over the past several years, and we have no intention of slowing down. Part of maintaining our market-leading position will involve continuing to enhance our technology. We've always been a company built on product excellence, and that will continue. As we move forward, we've learned that creating an optimal customer experience is very important. Now that our CGMs are mobile-based, we continue to look at how we can make life even better for diabetes patients. Nutrition is important to people with diabetes and those without. With this in mind, we have now added an AI provision where Dexcom G7 users can more easily log their nutrient intake by photographing their food with their smartphone. This is just one area we will continue to elaborate on to further improve the patient experience. As competition goes, there's more technology coming, but at the same time, we've invested billions of dollars in scaling our business. Scaling a CGM is not a simple task. We've built out a factory in Arizona and now have a factory in Malaysia that supplies more products, and we are working on finishing a factory in Ireland that we anticipate being at full scale by 2027. The scale of a CGM business to meet patient needs is really important, and I think that's a strong advantage for our team, and one we've built with our financial muscle and resources combined with our financial success in the marketplace. RL: What are Dexcom's current geographical focuses? KS: We are continuing to invest in the US, particularly as we have obtained much more coverage in the area of T2D for those not on insulin. We have a great market expansion opportunity in the US, and we've been able to obtain coverage from the three largest pharmacy benefit managers in the US for people with T2D who are not on insulin already. As for the rest of the world, the countries within Europe represent our next largest market, and we're continuing to focus on markets, particularly those where CGM is reimbursed. In the UK, we have Dexcom One Plus, which is lower cost, and while it doesn't connect with our automated insulin delivery system partners, it still provides patients with an optimal experience for managing their diabetes and gets reimbursed at a lower rate than our G7 product. We look at every country and the coverage available. There are other places where we've adopted an online strategy, originally, knowing there's no coverage, but if we go online and offer a cash paid product to individuals, they'll buy it. After a very long period of time, after people start buying the device online with their own money, the reimbursement authorities often come and cover the product. RL: What is your roadmap for Dexcom G7 and beyond? KS: Our next G7 product launch will be in the US, and we'll extend the device's lifespan out to 15 days. And that will be very important. Patients want it, and they don't want to change their sensor for this if they don't have to. Initially, for adults, the 15-day product will see a limited launch in the US in Q3, with a complete rollout expected by Q4. As mentioned, with respect to G7, we are continuing to enhance the app with the aforementioned AI function, and we plan to add more analytics to it over time. One thing we've done to improve the experience for a different group of customers are physicians. We're working hard on electronic healthcare record (EHR) integration. We have more than 100 clinics in the US in the process of or having integrating Dexcom CGM data into EPIC's EHR systems. And that'll be very important in the EU going forward, as many of the countries have talked about integrating sensor data with medical records. We have our Stelo device in the US, and we'll start rolling that out internationally in future periods. We've had great success with Stelo in the US so far, and we'll continue to expand that product offering, and again, add features and integrate more data to give people a better picture of their overall health. RL: Are there any plans to expand CGM into other indications such as health, wellness and metabolic health? KS: While we have not labelled anything for these indications, there is a migration towards them. We have API Interfaces that we share with several partners, and several of those apps that work with Stelo or G7 are, in fact, geared towards wellness and putting people in better overall metabolic health. We announced a recent partnership with ŌURA, for example, and Oura users are using Stelo and that Stelo data is displayed in the Oura ring app, along with Oura ring data, and those users will have their own insights as to what they think is most important concerning glucose data and other wellness metrics provided by Oura ring. RL: As a medtech CEO in this turbulent modern healthcare landscape, what keeps you up at night? KS: That's a good question, and those things have changed over the years, given that when I started with Dexcom, our revenue the previous year was $40m, and you can see where we are at now (Dexcom achieved revenues of around $4bn in 2024). One of the things I wake up and think about sometimes is that I want to make sure that, as a leader of this company, we don't miss the opportunity to change the lives of as many people as we can by not executing on our operations and having enough infrastructure in place to do the things we need to do. I think about that, and I think we've done a good job of scaling and building the business out to meet those requirements. We have to make sure we build a business that enables us to make our products more accessible to more people, to get them the clinical benefits of CGM, and at the same time, run a profitable business that generates proper returns to our shareholders. We've balanced this well over the years and will continue to do so. "Inside Dexcom's strategy to stay ahead in the $13.6bn CGM market" was originally created and published by Medical Device Network, a GlobalData owned brand. The information on this site has been included in good faith for general informational purposes only. It is not intended to amount to advice on which you should rely, and we give no representation, warranty or guarantee, whether express or implied as to its accuracy or completeness. You must obtain professional or specialist advice before taking, or refraining from, any action on the basis of the content on our site. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
a day ago
- Yahoo
Q&A: US ‘energy independence' more a political concept than a practical goal
US hydrocarbon production has steadily increased over the past couple of decades, driven by more sophisticated technology, an expansion of oil and gas infrastructure and a favourable regulatory environment. The Permian Basin remains the largest oil-producing shale play in the US, with global demand and geopolitical shifts continuing to support growth and competitiveness in the region, according to recent research from Offshore Technology's parent company, GlobalData. The region's crude oil production averaged 5.6 million barrels per day (mbbl/d) during the first quarter of 2024 (Q1 2024), accruing benefits from a dense pipeline network and Gulf Coast infrastructure. GlobalData oil and gas analyst Ravindra Puranik said: 'Europe's strategic shift away from Russian energy exports has resulted in key changes to the global energy supplies. This is anticipated to benefit the US shale oil and gas drillers, as well as LNG [liquefied natural gas] producers who are positioned to reap from these evolving supply chain dynamics." With this revolution in hydrocarbons, the US has been the world's biggest producer (as well as a substantial importer) for almost a decade, now extracting well over 13mbbl/d of crude oil. How will it maintain that position and what longer-term strategic issues does the country face? Mason Hamilton, vice-president of economics and research at the American Petroleum Institute (API), shares his insights with Offshore Technology. Ed Pearcey (EP): How has the US overtaken nations such as Saudi Arabia and Russia to become the world's largest oil and gas producer? Mason Hamilton (MH): This has been decades in the making. This goes back to the start of fracking technology, which was pioneered in the early 1950s by the US Department of Energy. Then, there was horizontal drilling technology. Those two were separate technologies and had separate pathways. In the past 20 years, those two technologies have been combined to give us a revolution and unlock a lot more of the resources already underneath our feet. Gas exports, particularly to Europe, have gone up quite substantially over the past five years. Collectively, Europe is the top destination for our LNG exports, particularly Germany, [which] has turned away from Russian gas. [The volume of US LNG exports to Germany reached 28.17 billion cubic feet in April, up from zero in 2022]. I believe in Q1 2025, [the US] also set a record high in the amount of LNG exports to places other than Europe, such as Asia and South America. EP: Are there any areas in the US that are primed for exploitation? MH: With acquiring resources, three main questions crop up: what's the available resource out there? Is there access to it? And, at what price can we get it? Alaska has a lot of potential. We saw the Willow project [an oil drilling initiative on the plain of the North Slope of Alaska in the state's National Petroleum Reserve, situated entirely on wetlands] with ConocoPhillips not too long ago. That was a big development there. There is also a lot of activity going on in federal lands. One of the of underlying themes that people are not aware of is that, since 2019, it is actually New Mexico that has seen the largest oil and gas production growth, not Texas. A huge chunk of the New Mexico production comes from federal lands in just three different counties. In fact, there is one county in the south-eastern corner of New Mexico, Lea County, that produces more crude oil than the five smallest OPEC [Organization of the Petroleum Exporting Countries] members. It produces over a million barrels a day. That growth was driven by access to and use of federal lands. If you look at the trends since the pandemic, the driving force that was really apparent post-Covid is increasing hydrocarbons production on federal lands. So, I would definitely say federal lands can be exploited further, because that is seen in the data. EP: Is the US nearing full energy independence? Doesn't the US still import certain types of crude oil? MH: Under Biden, there was a period of confusion and contention for us. Not only do we need continued certainty on access, but it is written into the law – that both onshore and offshore quarterly or yearly lease sales must be held – but in some years, they [the Biden administration] just didn't do it. We need to be clear – the term 'energy independence' is more or less a political slogan. From my perspective, the US is an active importer and exporter of energy, and an active trading partner when it comes to energy resources, whether that is electrons, petroleum, coal or so on. I think the terms 'energy security' and 'energy independence' are being used interchangeably. What we are really talking about is increased imports. I think between six and seven million barrels a day [we import], and I think 70% of that comes from Canada, while the second-largest imports origin point is Mexico. It is not like US is going far afield to get access to imported barrels – they are coming from North America. The marginal barrel, yes, probably does come from the Middle East, but far less than it did in the early 2000s or the 1980s or even 1970s, when we saw big gas lines during the energy crisis. In terms of energy security, yes, we are probably more energy secure now than in the past, but the term energy independence is just confusing – a misnomer. EP: Is there enough refinery capacity in the US? It needs to build more infrastructure such as refineries and storage facilities, so is that being worked on? MH: The US has not built any new major transportation, fuel-producing refineries since the late 1970s – but despite that, and despite many refineries closing over the past 30 years, the US has more refining capacity today than it did in the 1980s. That is because the refineries that we do have left have been heavily invested in, modernised and are equipped with the latest technology, meaning we can squeeze out every extra molecule. The US refinery fleet is one of the most modern in the world. Only last year, China managed to reach the same amount of refining capacity that we currently operate. The refining crown of the world is currently split between the US and China. China may have slightly more capacity, but US refineries run at a higher utilisation rate, typically in the 80% range, and sometimes even 90%. China simply does not achieve those kinds of run rates. The question of whether we need more refining capacity is not the right one. It should be 'Are we maximising the existing kit in the fleet that we have available?' I would flag one issue: we are losing refineries on the West Coast of the US, particularly in California, because of a very harsh regulatory environment, a harsh market environment, and other economic challenges such as refineries consuming a lot of electricity at a time when electricity prices in California are very high. With refinery closures in California, that market has become tight to the point where all of a sudden they must call up somewhere far, far away to get replacement supplies of gasoline. Could we build another refinery? Well, that depends on where it is, as the US is not one unified market for petroleum products, but five separate regions, namely the East Coast, Midwest, Gulf Coast, Rocky Mountain and West Coast. Nobody, as far as I know, is proposing a new greenfield refinery, but more refineries are being invested in, expanded upon and improved constantly. However, building a new refinery poses another question: do you build a refinery next to the source of demand, or do you build it next to the source of supply? EP: Are there any other markets, apart from Europe, to whom the US is looking to export its hydrocarbons? MH: It really depends on the product you are talking about. For LNG, Europe is a wide-open market. Increasingly, natural gas is going towards Europe. Then there are places such as India and South East Asia that are of interest. Some countries in South East Asia are on the cusp of needing to import energy rather than export, as their economies are growing, and their traditional fossil fuel resources and reserves have been depleted. Countries that come to mind are Malaysia, Indonesia, Thailand and Vietnam. They have significant energy resources; their production is now maybe on a downturn, but they have vibrant economies and still need power. Closer to home, South America is always a big market for us. In terms of Central and South America, a large portion of US petroleum product exports such as transportation fuels, gasoline and diesel go to Central and South American countries. In fact, over 50% of US gasoline exports go to one country: Mexico. Diesel is the most diverse US export product across all the energy commodities, because it goes to a long list of countries. So yes, the US is always looking to develop new markets in different places. "Q&A: US 'energy independence' more a political concept than a practical goal" was originally created and published by Offshore Technology, a GlobalData owned brand. The information on this site has been included in good faith for general informational purposes only. It is not intended to amount to advice on which you should rely, and we give no representation, warranty or guarantee, whether express or implied as to its accuracy or completeness. You must obtain professional or specialist advice before taking, or refraining from, any action on the basis of the content on our site.
